GE HealthCare Technologies Inc. Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)0.88 Intrinsic Value $79.31median of 6 methods · middle span $76-$104based on filings through 31 Mar 2026 Market Price $63.98Price as of 1 Oct 2026 UndervaluedIntrinsic value is 24% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $28.9B Enterprise Value $36.8B Shares Outstanding 456M diluted Moat Rating Narrow Next Earnings Date28 Oct 2026 Last ex-dividend24 Jul 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary GE HealthCare enters the second half of 2026 with strong demand indicators: record 11.1% organic orders growth, a 1.15 book-to-bill ratio, and $23.9 billion of backlog. Its innovation pipeline, pharmaceutical diagnostics franchise, advanced imaging portfolio, and expanding cloud and AI capabilities support durable growth. The offset is weaker Patient Care Solutions performance, input-cost inflation, and a second-quarter adjusted EBIT margin below the full-year guidance range. A Hold stance is appropriate pending evidence that backlog converts into profitable revenue and that margin recovery offsets PCS and inflation pressure. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$70.00 Mean target$82.50 High · most bullish analyst$96.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $70.0019% Book-to-bill falls below one as healthcare capital demand weakens, Patient Care Solutions remains in decline, and component, oil, and freight inflation exceeds management's approximately $250 million assumption, causing organic growth or adjusted EBIT margin to miss the lower end of guidance. Base CaseCentral scenario $82.5057% Matches the consensus meanGE HealthCare achieves its reaffirmed 2026 organic-growth and adjusted-margin ranges as strong Advanced Imaging Solutions and Pharmaceutical Diagnostics demand offsets continuing Patient Care Solutions weakness and input-cost inflation. Bull CaseUpside scenario $96.0024% Record orders convert efficiently, new imaging and pharmaceutical-diagnostics products sustain growth near or above the company's medium-term ambition, cloud and AI offerings increase recurring revenue, and decisive action on Patient Care Solutions improves consolidated profitability. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |